The Opportunities and Challenges of Outsourcing RBQM

About this session

Session: LEVERAGING QTLs AND KRIs FOR CLINICAL RISK DETECTION

Many organisations choose to outsource all or part of their RBQM to a CRO or vendor. How do you decide what to outsource? How do you know if the CRO/vendor will meet your requirements? How much input should the sponsor have? What are the best practices for oversight? This discussion will outline a variety of perspectives on the subject.

Speakers

• KD

  Keith Dorricott

  Director · Dorricott Metrics & Process Improvement Limited

  Moderator

• NB

  Natalia Buchneva

  Risk Mgmt Lead · UCB Pharma

  Panelist

• AK

  Amy R Kroeplin

  Senior Director · PPD Part of Thermo Fisher Scientific

  Panelist

• LW

  Linda White

  Associate Director · Jazz Pharmaceuticals Inc

  Panelist

• RO

  Rachel Oakley

  Associate Director · Regeneron Pharmaceuticals

  Panelist